Research Corporation Technologies

Research Corporation Technologies (RCT) is a technology investment and management company based in Tucson, Arizona, dedicated to advancing biomedical innovations. Founded in 1987, RCT focuses on providing early-stage funding and development for promising biomedical companies and technologies, particularly those originating from universities and research institutions worldwide. With assets exceeding $500 million, RCT supports the commercialization of academic innovations through venture investments, partnerships, and special licensing programs.

RCT's investment strategy encompasses a broad spectrum of stages, including seed, early stage, Series A, Series B, growth, and late stage. The firm has a diverse portfolio spanning various industries such as healthcare, biotechnology, medical devices, pharmaceuticals, diagnostics, life sciences, medical technology, oncology, genomics, biologics, cell and gene therapies, nanotechnology, exosome isolation, nanoparticle technology, and MedTech. This extensive focus reflects RCT's commitment to fostering innovation across the biomedical sector.

Over the years, RCT has demonstrated a strong track record in supporting the growth of its portfolio companies. Notable investments include Q'Apel Medical, Providence Medical Technology, BioCision, Esperance Pharmaceuticals, OrthAlign, VasoNova, Cylene Pharmaceuticals, ParinGenix, CryoFluor Therapeutics, Catalyst Biosciences, APT Pharmaceuticals, and Imagine Pharmaceuticals. These investments underscore RCT's dedication to advancing technologies with the potential to become significant biomedical products, thereby contributing to the evolution of the healthcare and life sciences industries.